InsiderTrades.com logo
Matthew Brams net worth and biography
  • LinkedIn
  • Phone
  • Email
  • Website

Matthew Brams Biography and Net Worth

Chief Medical Officer of Cingulate

Matthew Brams, MD is Chief Medical Officer and a Co-Founder of Cingulate Therapeutics. Dr. Brams is Medical Director and Principal of Bayou City Research, Inc. There, he has been instrumental in gaining FDA approval of over 15 Central Nervous System drugs currently in the marketplace. Dr. Brams is also a Clinical Associate Professor at the Menninger Department of Psychiatry of Baylor College of Medicine and has published over 20 peer-reviewed journal articles.

He has been lead investigator in several pivotal trials involving drugs in ADHD, autism, bipolar disorder and schizophrenia therapeutic areas. He has extensive experience in drug development and execution of Phase I-IV trials and has been involved in over 125 clinical trials in both adult and pediatric populations in all areas of psychiatry. In addition, he has over 25 years of clinical experience managing patients in the field of Adult and Child Psychiatry with particular expertise in ADHD and Autistic Spectrum Disorders (ASD).

He earned his MD from the University of Texas Health Science Center in Houston and completed his residencies at Baylor College of Medicine. He is Board certified in Adult and Child Psychiatry and is a Senior Board Examiner for the American Board of Psychiatry and Neurology.

What is Matthew Brams' net worth?

The estimated net worth of Matthew Brams is at least $24.19 thousand as of February 6th, 2026. Dr. Brams owns 4,656 shares of Cingulate stock worth more than $24,188 as of September 18th. This net worth estimate does not reflect any other investments that Dr. Brams may own. Learn More about Matthew Brams' net worth.

How do I contact Matthew Brams?

The corporate mailing address for Dr. Brams and other Cingulate executives is 1901 W. 47th Place, Kansas City, KS, 66205. Cingulate can also be reached via phone at 913-942-2300 and via email at [email protected]. Learn More on Matthew Brams' contact information.

Has Matthew Brams been buying or selling shares of Cingulate?

Matthew Brams has not been actively trading shares of Cingulate within the last three months. Most recently, on Friday, February 6th, Matthew Brams bought 1,946 shares of Cingulate stock. The stock was acquired at an average cost of $5.04 per share, with a total value of $9,807.84. Following the completion of the transaction, the executive vice president now directly owns 4,656 shares of the company's stock, valued at $23,466.24. Learn More on Matthew Brams' trading history.

Who are Cingulate's active insiders?

Cingulate's insider roster includes Matthew Brams (Chief Medical Officer), and Jennifer Callahan (Chief Financial Officer). Learn More on Cingulate's active insiders.

Are insiders buying or selling shares of Cingulate?

In the last year, Cingulate insiders bought shares 5 times. They purchased a total of 130,350 shares worth more than $656,964.00. The most recent insider tranaction occured on February, 13th when Director Thomas Jeffrey Hargroves bought 97,276 shares worth more than $490,271.04. Insiders at Cingulate own 5.3% of the company. Learn More about insider trades at Cingulate.

Information on this page was last updated on 2/13/2026.

Matthew Brams Insider Trading History at Cingulate

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
2/6/2026Buy1,946$5.04$9,807.844,656View SEC Filing Icon  
See Full Table

Matthew Brams Buying and Selling Activity at Cingulate

This chart shows Matthew Brams's buying and selling at Cingulate by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Cingulate Company Overview

Cingulate logo
Cingulate Inc., a biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of attention deficit/hyperactivity disorder and anxiety in the United States. The company's stimulant medications are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, as well as CTx-1302 (dextroamphetamine), which is in investigational new drug application development for the treatment of attention deficit/hyperactivity disorder intended for children, adolescents, and adults. It also focuses on developing CTx-2103 that is in a formulation stage for the treatment of anxiety. The company was founded in 2012 and is headquartered in Kansas City, Kansas.
Read More

Today's Range

Now: $5.26
Low: $5.09
High: $5.21

50 Day Range

MA: $5.03
Low: $4.43
High: $5.87

2 Week Range

Now: $5.26
Low: $3.16
High: $11.89

Volume

38,432 shs

Average Volume

410,439 shs

Market Capitalization

$76.49 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A